The jury is still out on whether colchicine will be clinically useful against COVID-19. Perhaps the strangest thing about COLCORONA is the decision to stop it early:

"On December 11, 2020, the steering committee chairman informed the data safety monitoring board that the investigators had decided to terminate the study once 75% of the planned patients were recruited and had completed the 30-day follow-up. This decision was made due to logistical issues related to maintaining the central study call center active 24 hours per day for a prolonged period of time, as well as the need to provide healthcare systems with study results in a timely fashion given the state of the COVID-19 pandemic."

In other words, they statistically shot themselves in the foot.

As you can see in the study paper below, promising data on reducing hospitalizations and deaths in those with PCR confirmed COVID-19 but not yet hospitalized. Sure, one can haggle about absolute and relative risk reductions as that article that Fouremm shared does, but still in this pandemic day and age a drug to keep folks out of the hospital and potentially from death sounds promising.....even with the diarrhea side effect! However, now with so many vaccines getting in arms and vaccines working to reduce hospitalizations and deaths.....this approach of drugging every case of COVID-19 with colchicine may not be as attractive.

https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1.full.pdf

Of note, another colchicine study is ongoing that is only treating those hospitalized. This would be analagous to the Phase 2 trial that Resverlogix is about to launch for apabetalone.

BDAZ